These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 17943530)

  • 21. Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview.
    So WK; Cheng JC; Poon SL; Leung PC
    FEBS J; 2008 Nov; 275(22):5496-511. PubMed ID: 18959739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
    Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
    Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effect of GnRH agonist in epithelial ovarian cancer.
    Kim JH; Park DC; Kim JW; Choi YK; Lew YO; Kim DH; Jung JK; Lim YA; Namkoong SE
    Gynecol Oncol; 1999 Aug; 74(2):170-80. PubMed ID: 10419728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
    Emons G; Kaufmann M; Gorchev G; Tsekova V; Gründker C; Günthert AR; Hanker LC; Velikova M; Sindermann H; Engel J; Schally AV
    Gynecol Oncol; 2010 Dec; 119(3):457-61. PubMed ID: 20828803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity.
    Gebauer G; Mueller N; Fehm T; Berkholz A; Beck EP; Jaeger W; Licht P
    Am J Obstet Gynecol; 2004 Jun; 190(6):1621-8; discussion 1628. PubMed ID: 15284756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
    Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
    Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GnRH analogs reduce invasiveness of human breast cancer cells.
    von Alten J; Fister S; Schulz H; Viereck V; Frosch KH; Emons G; Gründker C
    Breast Cancer Res Treat; 2006 Nov; 100(1):13-21. PubMed ID: 16758121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral level of gonadotropin-releasing hormone in ovarian and endometrial cancers.
    Furui T; Imai A; Tamaya T
    Oncol Rep; 2002; 9(2):349-52. PubMed ID: 11836606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of growth and proliferation of EcRG293 cell line expressing high-affinity gonadotropin-releasing hormone (GnRH) receptor under the control of an inducible promoter by GnRH agonist (D-Lys6)GnRH and antagonist (Antide).
    Kakar SS
    Cancer Res; 1998 Oct; 58(20):4558-60. PubMed ID: 9788600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells.
    Gründker C; Günthert AR; Hellriegel M; Emons G
    Eur J Endocrinol; 2004 Nov; 151(5):619-28. PubMed ID: 15538941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
    Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
    Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
    Gründker C; Günthert AR; Millar RP; Emons G
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1427-30. PubMed ID: 11889221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of gonadotropin-releasing hormone-I agonist and gonadotropin-releasing hormone-II on endometrial carcinoma cell lines with different states of PTEN].
    Zhao LJ; Wei LH; Li XP; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):45-9. PubMed ID: 19563062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
    Schubert A; Hawighorst T; Emons G; Gründker C
    Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
    Gewirtz DA; Di X; Walker TD; Sawyer ST
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.
    Engel JB; Hahne JC; Häusler SF; Meyer S; Segerer SE; Diessner J; Dietl J; Honig A
    Anticancer Res; 2012 May; 32(5):2063-8. PubMed ID: 22593489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.